|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,801.00 GBX | -0.19% |
|
-0.85% | -1.29% |
| 24/01 | The weekly recap: Things really heated up… for a chunk of ice |  |
| 23/01 | GSK Says China Approves Trelegy Ellipta for Adults With Uncontrolled Asthma | MT |
| Capitalization | 72.26B 98.09B 83.42B 77.32B 135B 9,012B 143B 884B 351B 4,255B 368B 360B 15,478B | P/E ratio 2025 * |
13.3x | P/E ratio 2026 * | 11.5x |
|---|---|---|---|---|---|
| Enterprise value | 86.39B 117B 99.74B 92.45B 161B 10,774B 171B 1,057B 419B 5,087B 440B 431B 18,504B | EV / Sales 2025 * |
2.66x | EV / Sales 2026 * | 2.47x |
| Free-Float |
94.52% | Yield 2025 * |
3.6% | Yield 2026 * | 3.87% |
Last Transcript: GSK plc
| 23/01 | GSK : JP Morgan reiterates its Sell rating | ZD |
| 21/01 | GSK : UBS remains Neutral | ZD |
| 21/01 | Top Midday Gainers | MT |
| 21/01 | GSK : Receives a Sell rating from Barclays | ZD |
| 16/01 | GSK : UBS sticks Neutral | ZD |
| 1 day | -0.19% | ||
| 1 week | -0.85% | ||
| Current month | -1.29% | ||
| 1 month | -0.74% | ||
| 3 months | +9.38% | ||
| 6 months | +31.32% | ||
| Current year | -1.29% |
| 1 week | 1,774 |  | 1,816 |
| 1 month | 1,774 | | 1,909.73 |
| Current year | 1,774 | | 1,909.73 |
| 1 year | 1,242.5 | | 2,057.7 |
| 3 years | 1,242.5 | | 2,057.7 |
| 5 years | 1,242.5 | | 3,408.16 |
| 10 years | 1,242.5 | | 3,408.16 |
| Manager | Title | Age | Since |
|---|---|---|---|
Luke Miels
CEO | Chief Executive Officer | - | 01/01/2026 |
Julie Brown
DFI | Director of Finance/CFO | 64 | 01/05/2023 |
| Chief Tech/Sci/R&D Officer | - | 01/12/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Hal Barron
BRD | Director/Board Member | 64 | 01/01/2018 |
Jonathan Symonds
CHM | Chairman | 68 | 01/09/2019 |
Charles Bancroft
BRD | Director/Board Member | 66 | 01/05/2020 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +0.75% | 3.15% | 26 M€ | |
| -0.45% | 2.97% | 64 M€ | |
| +5.88% | 2.51% | 8 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.19% | -0.85% | +32.09% | +27.66% | 98.09B | |
| -2.12% | +2.49% | +38.83% | +211.00% | 953B | |
| +0.76% | +0.68% | +50.12% | +30.79% | 530B | |
| +0.53% | +2.29% | +28.47% | +47.60% | 388B | |
| +0.06% | -0.23% | +26.86% | +17.82% | 377B | |
| +0.15% | -3.36% | +22.94% | +23.03% | 286B | |
| +0.47% | +0.03% | +28.12% | +35.36% | 281B | |
| +1.17% | +3.20% | -30.92% | -16.86% | 281B | |
| -0.92% | -0.60% | +11.95% | -1.55% | 269B | |
| -0.67% | +4.34% | +24.06% | +32.10% | 186B | |
| Average | -0.08% | +0.58% | +23.25% | +40.70% | 364.85B | |
| Weighted average by Cap. | -0.35% | +0.86% | +27.78% | +71.98% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 32.5B 44.11B 37.52B 34.78B 60.58B 4,053B 64.21B 397B 158B 1,914B 165B 162B 6,961B | 34.01B 46.17B 39.27B 36.4B 63.41B 4,242B 67.21B 416B 165B 2,003B 173B 170B 7,286B |
| Net income | 5.49B 7.46B 6.34B 5.88B 10.24B 685B 10.85B 67.17B 26.67B 323B 27.96B 27.39B 1,177B | 6.23B 8.45B 7.19B 6.67B 11.61B 777B 12.31B 76.17B 30.24B 367B 31.7B 31.05B 1,334B |
| Net Debt | 14.13B 19.18B 16.31B 15.12B 26.34B 1,762B 27.92B 173B 68.61B 832B 71.92B 70.45B 3,027B | 11.72B 15.9B 13.53B 12.54B 21.84B 1,461B 23.15B 143B 56.88B 690B 59.63B 58.41B 2,510B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23/01/26 | 1,801.00 p | -0.19% | 9,063,476 |
| 22/01/26 | 1,804.50 p | +0.95% | 4,821,354 |
| 21/01/26 | 1,787.50 p | -0.45% | 6,415,514 |
| 20/01/26 | 1,795.50 p | -1.13% | 7,499,503 |
| 19/01/26 | 1,816.00 p | -0.03% | 5,057,573 |
Delayed Quote London S.E., 24 January 2026 at 03:35 am AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- GSK Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition